Results 131 to 140 of about 4,326,321 (342)

Early Intensive Versus Escalation Approach: Ten‐Year Impact on Disability in Relapsing Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the long‐term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high‐efficacy disease‐modifying therapies (HE‐DMTs) on disability progression in relapsing multiple sclerosis (RMS). Methods This observational study included 4878 RMS patients from the Italian Multiple Sclerosis Register ...
Pietro Iaffaldano   +47 more
wiley   +1 more source

Massachusetts Health Care Reform: Six Years Later [PDF]

open access: yes, 2012
Examines Massachusetts' implementation of healthcare reform since 2006 and outcomes to date, including expansion of coverage, gains in access to care, ongoing issues with rising costs, and changes needed to comply with federal healthcare ...

core  

Remaining Burden of Spinal Muscular Atrophy Among Treated Patients: A Survey of Patients and Caregivers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Spinal muscular atrophy (SMA) significantly impacts motor function. This study aimed to assess the persistent burden and unmet needs among currently treated patients with SMA and their caregivers. Methods Two complementary web‐based surveys were distributed in August 2024 among patients with SMA and their caregivers.
Julie A. Parsons   +8 more
wiley   +1 more source

Healthcare regulation: Past, Present, and Future [PDF]

open access: bronze, 1994
Barbara Ross-Lee, Michael A. Weiser
openalex   +1 more source

Information systems and healthcare XXIV: Factors affecting the EAI adoption in the healthcare sector [PDF]

open access: yes, 2008
Recent developments in the field of integration technologies like Enterprise Application Integration (EAI) have emerged to support organizations towards improving the quality of services and reducing integration costs.
Irani, Z   +3 more
core   +2 more sources

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

Leadership for healthcare [PDF]

open access: yesInternational Journal of Integrated Care, 2011
Amy Tan Bee Choo, Jason Cheah
openaire   +5 more sources

Home - About - Disclaimer - Privacy